Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis.
Recently, a novel class of angiostatic steroids which block angiogenesis in several systems has been described. Since the elaboration of proteases is believed to be an important component of angiogenesis, we tested whether these steroids blocked the fibrinolytic response of endothelial cells to the angiogenic protein, basic fibroblast growth factor [bFGF]). Cultured bovine aortic endothelial (BAE) cells were incubated with bFGF and/or medroxyprogesterone acetate (MPA), an angiostatic steroid which has been shown to inhibit vascularization, collagenolysis, and tumor growth. When bFGF (3 ng/ml) was added to confluent monolayers of BAE cells, plasminogen activator (PA) activity in the medium was increased threefold. In contrast, MPA at 10(-6) M, 10(-7) M, 10(-8) M, and 10(-9) M decreased PA levels in the medium by 83%, 83%, 75%, and 39%, respectively. The stimulation of PA levels in BAE cells by bFGF (3 ng/ml) was abrogated by the presence of 10(-6) M MPA. This decrease in PA activity was found to be mediated by a significant increase in plasminogen activator inhibitor type-1 (PAI-1) production. MPA, therefore, negated one of the important enzymatic activities associated with the angiogenic process. In contrast to the decreased levels of secreted PA in cultures exposed simultaneously to MPA and bFGF, cell-associated PA levels remained high, consistent with earlier observations indicating that PAI-1 does not inhibit cell-associated PA. Thus, angiostatic steroids may exert their inhibitory effects on angiogenesis by increasing the synthesis of PAI-1. This, in turn, inhibits PA activity and, therefore, plasmin generation, which is essential for the invasive aspect of angiogenesis.
Blei
F
F
Department of Pediatrics, New York University Medical Center, New York, New York.
Wilson
E L
EL
Mignatti
P
P
Rifkin
D B
DB
D019326:17-alpha-Hydroxyprogesterone; D000818:Animals; D001011:Aorta; D002417:Cattle; D002478:Cells, Cultured; D003907:Dexamethasone / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006854:Hydrocortisone / Q000494:pharmacology; D006908:Hydroxyprogesterones / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000494:pharmacology; D009389:Neovascularization, Pathologic; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis*; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013256:Steroids / Q000494:pharmacology*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D006908:Hydroxyprogesterones; D017395:Plasminogen Activator Inhibitor 1; D013256:Steroids; D016222:Fibroblast Growth Factor 2; D019326:17-alpha-Hydroxyprogesterone; D003907:Dexamethasone; D006493:Heparin; D017258:Medroxyprogesterone Acetate; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D006854:Hydrocortisone